Ovarian cancer risk after the use of ovulation-stimulating drugs

Obstetrics and Gynecology

Volumn 103, Issue 6, 2004, Pages 1194-1203

  Brinton, Louise A ^a   Lamb, Emmet J ^a   Moghissi, Kamran S ^a   Scoccia, Bert ^a   Althuis, Michelle D ^a   Mabie, Jerome E ^a   Westhoff, Carolyn L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; GONADOTROPIN; FERTILITY PROMOTING AGENT;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; OVARY CANCER; OVULATION INDUCTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CHEMICALLY INDUCED DISORDER; FEMALE INFERTILITY; FOLLOW UP; INCIDENCE; OVARY TUMOR; REGISTER; RISK; STATISTICS; TIME;

ADULT; CLOMIPHENE; COHORT STUDIES; FEMALE; FERTILITY AGENTS, FEMALE; FOLLOW-UP STUDIES; GONADOTROPINS; HUMANS; INCIDENCE; INFERTILITY, FEMALE; OVARIAN NEOPLASMS; OVULATION INDUCTION; REGISTRIES; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 3042631539     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000128139.92313.74     Document Type: Article

References (37)

1. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994;140:585-97.
2. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
3. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet 1971;2:163.
4. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-20.
5. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-6.
6. Whittemore AS, Harris R, Itnyre J, for the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-203.
7. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-7.
8. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-13.
9. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994;9:1673-5.
10. Klip H, Burger CW, van Leeuwen FE, for the OMEGA Project Group. Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilisation in a cohort of 25,152 women. Enschede, the Netherlands: PrintPartners Ipskamp BV; 2002. p. 55-82.
11. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-42.
12. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Anderson AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005-12.
13. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-24.
14. Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignanci PG. Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 1997;12:2159-61.
15. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld B, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999;71:853-9.
16. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-90.
17. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13-8.
18. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995-1000.
19. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-90.
20. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176:572-9.
21. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.
22. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003;189:289-94.
23. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995;4:447-51.
24. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-9.
25. Breslow NE, Day NE. The design and analysis of cohort studies. Vol 2. Statistical methods in cancer research. Lyon, France: International Agency for Research on Cancer; 1987.
26. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiol Rev 1998;20:237-57.
27. Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 2000;11:319-44.
28. Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 1998;68:226-8.
29. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204-11.
30. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta Obstet Gynecol Scand 1982;61:261-3.
31. Balasch J, Pahisa J, Marquez M, Ordi J, Fabregues F, Puerto B, et al. Metastatic ovarian strumosis in an in-vitro fertilization patient. Hum Reprod 1993;8:2075-7.
32. Bamford PN, Steele SJ. Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy. Br J Obstet Gynaecol 1982;89:962-4.
33. Ben-Hur H, Dgani R, Lancet M, Katz Z, Nissim F, Rosenman D. Ovarian cancer masquerading as ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 1986;65:813-4.
34. Carter ME, Joyce DN. Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: a case report. J In Vitro Fertil Embryo Transf 1987;4:126-8.
35. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? BMJ 1989;299:309-11.
36. Goldberg GL, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation: is there a link? Am J Obstet Gynecol 1992;166:853-4.
37. Willemsen W, Kruitwagen R, Bastiaans B, Hanselaar T, Rolland R. Ovarian stimulation and granulosa-cell tumor. Lancet 1993;341:986-8.